The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.

BMC Pharmacology & Toxicology
Boyu LiLihong Liu

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrated good glycemic efficacy in patients with type 2 diabetes mellitus (T2DM) recent years, whereas studies on GLP-1 RAs' biliary effects were limited. Therefore, we aimed to assess the effect of exenatide on bile acids (BAs) and investigate the role of BAs in the glycemic control effect of exenatide. Thirty-eight newly diagnosed T2DM participants without glucose-lowering drugs intake were recruited. Plasma total bile acids in fasting state (FTBAs) and other parameters were tested at baseline. Then exenatide were applied to the T2DM participants for 12 weeks. FTBAs and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of FTBAs and glycemic parameters were conducted to investigate the role of BAs in the glycemic control effect of exenatide. The baseline FTBAs level of T2DM patients had no significance (3.84 ± 2.06 vs. 3.87 ± 2.89, P = 0.954) compared with healthy subjects. After 12-week exenatide treatment for the T2DM patients, FTBAs were decreased from 3.84 ± 2.06 μmol/L to 3.06 ± 1.27 μmol/L (P < 0.01). The correlation analysis showed that changes of FTBAs was positively correlated with changes of FPG (r = 0....Continue Reading

Associated Clinical Trials

References

Aug 14, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·J H ScarpelloH C Howlett
May 20, 2008·Cellular and Molecular Life Sciences : CMLS·A F Hofmann, L R Hagey
Jan 8, 2009·Physiological Reviews·Philippe LefebvreBart Staels
Sep 3, 2009·Cell Metabolism·Charles ThomasKristina Schoonjans
Apr 29, 2010·American Journal of Physiology. Endocrinology and Metabolism·Filip K Knop
Aug 29, 2013·Nature Reviews. Gastroenterology & Hepatology·Frank G SchaapPeter L M Jansen
Apr 4, 2014·European Journal of Internal Medicine·Asger LundTina Vilsbøll
Jul 6, 2014·PloS One·Antonella NapolitanoDerek J Nunez
Jul 23, 2015·BMC Cardiovascular Disorders·Mats RudlingLeif Rikner
Aug 4, 2015·Cell Metabolism·Evie P M BroedersPatrick Schrauwen
Dec 5, 2015·Diabetes, Obesity & Metabolism·Marcel H A MuskietDaniël H van Raalte
Mar 18, 2017·Diabetes, Obesity & Metabolism·Martin L KårhusFillip K Knop
Nov 23, 2017·Frontiers in Neuroscience·Kim L MertensHannah M Eggink
Jan 18, 2018·The Journal of Experimental Medicine·Hagit ShapiroEran Elinav
Apr 24, 2018·Pharmacology & Therapeutics·Qinwei YuLuyong Zhang

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Expert Opinion on Investigational Drugs
James MaloneDavid M Kendall
Nature Reviews. Drug Discovery
Mayer B DavidsonPeter Kirkpatrick
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Zin Z HtikeMelanie Davies
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Katherine V Mann, Philip Raskin
© 2022 Meta ULC. All rights reserved